CureVac (NASDAQ:CVAC) shares shot up 2.6% during mid-day trading on Thursday . The company traded as high as $55.20 and last traded at $55.09. 217 shares traded hands during trading, a decline of 100% from the average session volume of 1,152,690 shares. The stock had previously closed at $53.67.
A number of brokerages have recently issued reports on CVAC. Guggenheim assumed coverage on shares of CureVac in a research note on Monday, May 3rd. They set a “buy” rating for the company. Berenberg Bank set a $123.00 price target on shares of CureVac and gave the stock a “buy” rating in a research report on Thursday, July 1st. Evercore ISI reaffirmed a “buy” rating on shares of CureVac in a research report on Monday, July 5th. Bank of America cut shares of CureVac from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Thursday, June 17th. Finally, Credit Suisse Group assumed coverage on shares of CureVac in a research report on Monday, April 26th. They issued an “underperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $80.80.
The company’s fifty day simple moving average is $84.70. The company has a current ratio of 5.61, a quick ratio of 5.55 and a debt-to-equity ratio of 0.04. The firm has a market cap of $10.17 billion and a PE ratio of -49.19.
CureVac Company Profile (NASDAQ:CVAC)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza.
Read More: Cost of Capital
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.